echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Significantly reduce the risk of lung cancer! AZ anti PD-L1 drug phase 3 was a great success

    Significantly reduce the risk of lung cancer! AZ anti PD-L1 drug phase 3 was a great success

    • Last Update: 2017-05-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: the field of cancer immunotherapy of Wuxi apptec on May 15, 2017 has seen a surge in recent years This week, a new anti PD-L1 drug jointly developed by Merck KGaA and Pfizer in Germany was approved for the treatment of advanced bladder cancer, and MSD's anti PD- 1 immunotherapy for lung cancer was also approved by the U.S FDA AstraZeneca welcomed the approval of its first immunotherapy drug, imfinzi (durvalumab), in May, and announced today that durvalumab has made breakthrough progress in a phase 3 clinical trial of non-small cell lung cancer (NSCLC) with its biological drug research and development organization, MedImmune It is also expected that durvalumab will be approved by the US FDA to treat non-small cell lung cancer Lung cancer is one of the leading causes of cancer death in the world According to the report of cancer facts & figures 2017 released by the American Cancer Society, lung cancer is the cancer that causes the most deaths in both men and women In lung cancer, about 85% of the cases are non-small cell lung cancer, which is famous for its difficulty in treatment In all the new cases of lung cancer, about one third of the patients are diagnosed with stage III disease Nearly half of the patients with stage III lung cancer can not be removed, so the prognosis is not optimistic The 5-year survival rate is only 10% - 23% on average For these patients, the new therapy is the best hope to maintain life, and the recent hot immunotherapy, also let them see the dawn of prolonging life Durvalumab, brought by AstraZeneca, is such an immunotherapy drug that is expected to bring hope to cancer patients As a humanized monoclonal antibody against PD-L1 protein, it can directly bind to PD-L1 protein and inhibit its binding to PD-1 protein and CD80 on the surface of T cells Tumor cells can not use PD-L1 / PD-1 pathway to escape the pursuit of the immune system Durvalumab also uses this mechanism to activate the immune system and kill tumors Previously, it has obtained the qualification of breakthrough therapy identification and priority review issued by the FDA of the United States In a report this year, it was also listed as one of the potentially heavyweight drugs expected to go on the market in 2017 Today, AstraZeneca and MedImmune announced that durvalumab has achieved excellent results in the treatment of non-small cell lung cancer patients in a phase 3 clinical trial called Pacific The study is a randomized, double-blind, placebo-controlled, multicenter clinical trial in which patients with locally advanced, unresectable (phase III) NSCLC are recruited from 26 countries around the world After receiving standard chemotherapy and radiotherapy containing platinum, their condition has not progressed Durvalumab, as a follow-up treatment, was further treated After a mid-term examination, an independent data monitoring committee (IDMC) believed that in this clinical trial, compared with the control group, patients treated with durvalumab had a statistically and clinically significant improvement in PFS, which also reached the main end point of this clinical trial It is worth mentioning that durvalumab is the first tumor immunotherapy drug to show excellent progression free survival improvement in this patient's background AstraZeneca plans to present and publish the preliminary results of the clinical trial at a recent medical conference ▲ Dr Sean bohen, executive vice president and chief medical officer of AstraZeneca in charge of global drug development (photo source: AstraZeneca) Dr Sean bohen, executive vice president and chief medical officer of AstraZeneca in charge of global drug development, said: "it is a very exciting result for patients who have advanced lung cancer and cannot be treated by surgery We look forward to working with global regulators to deliver imfinzi to lung cancer patients as soon as possible In addition, we plan to explore the full potential of imfinzi as a single therapy, as well as a combination therapy with drugs such as tremelimumab, to meet the needs of multiple types of cancer " Currently, researchers are using durvalumab as a single therapy to test its efficacy in a variety of non-small cell lung cancer, small cell lung cancer, urothelial bladder cancer, and squamous cell carcinoma of the head and neck In addition, it also combined with tremelimumab, a CTLA-4 inhibitor, to treat urothelial bladder cancer, non-small cell lung cancer, small cell lung cancer, head and neck squamous cell carcinoma in phase 3 clinical trials, and gastric cancer, pancreatic cancer, liver cancer, and blood cancer in phase 1 / 2 clinical trials We congratulate durvalumab on its outstanding performance in phase 3 clinical practice, and wish more and more immunotherapies can be successfully launched in the market, bringing hope for the treatment of cancer patients!
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.